Desmoteplase
Desmoteplase[edit | edit source]
Desmoteplase is a thrombolytic agent derived from the saliva of the Desmodus rotundus, commonly known as the vampire bat. It is a plasminogen activator that has been studied for its potential use in treating ischemic stroke.
Mechanism of Action[edit | edit source]
Desmoteplase functions by activating plasminogen to plasmin, an enzyme that breaks down fibrin clots. Unlike other thrombolytics, desmoteplase is highly specific for fibrin-bound plasminogen, which minimizes the risk of systemic bleeding. This specificity is due to its unique structure, which allows it to bind selectively to fibrin-rich clots.
Clinical Applications[edit | edit source]
Desmoteplase has been investigated in clinical trials for the treatment of acute ischemic stroke. Its ability to dissolve clots without significant neurotoxicity or hemorrhagic transformation makes it a promising candidate for stroke therapy. However, its clinical development has faced challenges, and further studies are needed to establish its efficacy and safety.
Advantages over Other Thrombolytics[edit | edit source]
Compared to traditional thrombolytics like alteplase, desmoteplase offers several potential advantages:
- Higher Fibrin Specificity: Desmoteplase targets fibrin-bound plasminogen more selectively, reducing the risk of bleeding.
- Longer Half-Life: It has a longer half-life, allowing for a more extended therapeutic window.
- Reduced Neurotoxicity: Studies suggest that desmoteplase may have a lower risk of causing neurotoxic effects.
Challenges and Limitations[edit | edit source]
Despite its potential benefits, desmoteplase has encountered several challenges in clinical trials. These include:
- Variable Efficacy: Some trials have shown inconsistent results regarding its effectiveness in improving clinical outcomes.
- Regulatory Hurdles: Approval processes have been complicated by the need for more robust data on safety and efficacy.
Future Directions[edit | edit source]
Ongoing research aims to better understand the pharmacodynamics of desmoteplase and optimize its use in clinical settings. Combination therapies and improved delivery methods are being explored to enhance its therapeutic potential.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
